5-二叔丁基膦-1′,3′,5′-三苯基-1′H-[1,4′]二吡唑 | 894086-00-1

• 物质功能分类: 有机原料 - 有机膦化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-二叔丁基膦-1′,3′,5′-三苯基-1′H-[1,4′]二吡唑
• 中文别名: 5-二叔丁基膦-1',3',5'-三苯基-1'H-[1,4']二吡唑
• 英文名称: 5-(di-tert-butylphosphino)-1′, 3′, 5′-triphenyl-1′H-[1,4′]bipyrazole
• 英文别名: 5-(di-tert-butylphosphino)-1′,3′,5′-triphenyl-1′H-[1,4′]-bipyrazole；5-(di-tert-butylphosphino)-1′,3′,5′-triphenyl-1′H-[1,4′]bipyrazole；5-(di-tert-butylphosphino)-1′,3′,5′-triphenyl-1′H-1,4-bipyrazole；5-(di-tert-butylphosphino)-1′,3′,5′-triphenyl-1,4′bi-1H-pyrazole；5-(di-t-butylphosphino)-1′,3′,5′-triphenyl-1,4′-bi-1H-pyrazole；5-(di-tert-butylphosphino)-1-(1,3,5-triphenyl-1H-pyrazol-4-yl)-1H-pyrazole；5-(di-tert-Butylphosphino)-1',3',5'-triphenyl-1'H-1,4'-bipyrazole；ditert-butyl-[2-(1,3,5-triphenylpyrazol-4-yl)pyrazol-3-yl]phosphane
• CAS: 894086-00-1
• 化学式: C₃₂H₃₅N₄P
• 分子量: 506.63
• InChiKey: PTXJGGGNGMPMBG-UHFFFAOYSA-N

物化性质

• 熔点：
  169-173 °C
• 沸点：
  652.7±55.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.6
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• TSCA：
  No
• 安全说明：
  S26,S37
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

---

Section 1: Product Identification
Chemical Name: 5-(Di-t-butylphosphino)-1',3',5'-triphenyl-1,4'-bi-1H-pyrazole, min. 95% t-Bu-BippyPhos
CAS Registry Number: 894086-00-1
Formula: C32H35N4P
EINECS Number: none
Chemical Family: organophosphine salt
Synonym: y-Bu-BippyPhos; 5-(Di-tert-butyl-phosphanyl)-1',3',5'-triphenyl-1'H-[1,4']bipyrazolyl

---

Section 2: Composition and Information on Ingredients
Ingredient CAS Number Percent ACGIH (TWA) OSHA (PEL)
Title compound 894086-00-1 100% no data no data

---

Section 3: Hazards Identification
Emergency Overview: Irritating to skin, eyes and respiratory tract.
Primary Routes of Exposure: Ingestion, inhalation
Eye Contact: Causes slight to mild irritation of the eyes.
Skin Contact: Causes slight to mild irritation of the skin.
Inhalation: Irritating to the nose, mucous membranes and respiratory tract.
Ingestion: No information available on the physiological effects of ingestion. May be harmful if swallowed.
Acute Health Affects: Irritating to skin, eyes and respiratory tract.
Chronic Health Affects: No information on long-term chronic effects.
NTP: No
IARC: No
OSHA: No

---

SECTION 4: First Aid Measures
Immediately flush the eyes with copious amounts of water for at least 10-15 minutes. A victim may need
Eye Exposure:
assistance in keeping their eye lids open. Get immediate medical attention.
Wash the affected area with water. Remove contaminated clothes if necessary. Seek medical assistance if
Skin Exposure:
irritation persists.
Remove the victim to fresh air. Closely monitor the victim for signs of respiratory problems, such as difficulty
Inhalation:
in breathing, coughing, wheezing, or pain. In such cases seek immediate medical assistance.
Seek medical attention immediately. Keep the victim calm. Give the victim water (only if conscious). Induce
Ingestion:
vomiting only if directed by medical personnel.

---

SECTION 5: Fire Fighting Measures
Flash Point: no data
Autoignition Temperature: no data
Explosion Limits: no data
Extinguishing Medium: carbon dioxide, dry powder or foam
If this product is involved in a fire, fire fighters should be equipped with a NIOSH approved positive pressure
Special Fire Fighting Procedures:
self-contained breathing apparatus and full protective clothing.
Hazardous Combustion and If involved in a fire this material may emit irritating fumes.
Decomposion Products:
Unusual Fire or Explosion Hazards: No unusual fire or explosion hazards.

---

SECTION 6: Accidental Release Measures
Spill and Leak Procedures: Small spills can be mixed with vermiculite or sodium carbonate and swept up.

---

SECTION 7: Handling and Storage
The material will degrade on prolonged exposure to air. Store in a tightly sealed container under an inert
Handling and Storage:
atmosphere of nitrogen or argon.

---

SECTION 8: Exposure Controls and Personal Protection
Eye Protection: Always wear approved safety glasses when handling a chemical substance in the laboratory.
Skin Protection: Wear protective clothing and gloves.
Ventilation: Handle the material in an efficient fume hood.
If ventilation is not available a respirator should be worn. The use of respirators requires a Respirator
Respirator:
Protection Program to be in compliance with 29 CFR 1910.134.
Ventilation: Handle the material in an efficient fume hood.
Additional Protection: No additional protection required.

---

SECTION 9: Physical and Chemical Properties
Color and Form: white powder
Molecular Weight: 506.62
Melting Point: 169-173°
Boiling Point: no data
Vapor Pressure: no data
Specific Gravity: no data
Odor: none
Solubility in Water: insoluble

---

SECTION 10: Stability and Reactivity
Stability: air sensitive
Hazardous Polymerization: no hazardous polymerization
Conditions to Avoid: prolonged exposure to air
Incompatibility: strong oxidizing agents
Decomposition Products: carbon monoxide, carbon dioxide, phosphorus oxides and organic fumes

---

SECTION 11: Toxicological Information
RTECS Data: No information available in the RTECS files.
Carcinogenic Effects: no data
Mutagenic Effects: no data
Tetratogenic Effects: no data

---

SECTION 12: Ecological Information
Ecological Information: No information available

---

SECTION 13: Disposal Considerations
Disposal: Dispose of according to local, state and federal regulations.

---

SECTION 14: Transportation
Shipping Name (CFR): Non-hazardous
Hazard Class (CFR): NA
Additional Hazard Class (CFR): NA
Packaging Group (CFR): NA
UN ID Number (CFR): NA
Shipping Name (IATA): Non-hazardous
Hazard Class (IATA): NA
Additional Hazard Class (IATA): NA
Packaging Group (IATA): NA
UN ID Number (IATA): NA

---

SECTION 15: Regulatory Information
TSCA: Not listed in the TSCA inventory
SARA (Title 313): Title compound not listed
Second Ingredient: none

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

在化学合成领域，5-二叔丁基膦-1',3',5'-三苯基-1'H-[1,4']二吡唑可用作催化剂，促进酯化反应、氢化反应等多种有机合成反应的进行。

在材料科学领域，这种化合物可以与金属离子形成发光材料。这些材料广泛应用于荧光探针、生物成像和显示技术等领域，并且还可以用于制备高分子材料、纳米材料等新型材料。

此外，在生物医药领域，5-二叔丁基膦-1',3',5'-三苯基-1'H-[1,4']二吡唑作为一种新型药物载体或药物分子展现出潜力。由于其良好的稳定性和反应活性，它可以与多种药物分子结合，形成具有特定功能的药物复合物。这些药物复合物在体内能够发挥更好的治疗效果，并有助于减少副作用和毒性。

反应信息

• 作为反应物：
  描述：

  5-二叔丁基膦-1′,3′,5′-三苯基-1′H-[1,4′]二吡唑 在 双氧水 作用下， 以 水 、 乙腈 为溶剂， 反应 0.17h， 以91.6%的产率得到di-tert-butyl(1',3',5'-triphenyl-1'H-[1,4'-bipyrazol]-5-yl)-phosphine oxide
  参考文献：
  名称：

  Effects of Multiple Catalyst Deactivation Pathways and Continuous Ligand Recycling on the Kinetics of Pd-Catalyzed C–N Coupling Reactions

  摘要：

  Unusual Pd deactivation and inhibition pathways were observed in a C-N coupling system. Irreversible catalyst deactivation involved C-H insertion of Pd into BippyPhos leading to an off-cycle palladaphosphacyclobutene. Product inhibition led to deactivated Pd but released ligand in the process, allowing it to react with additional Pd precursor to re-enter the catalytic cycle. In situ recycling of the ligand allowed for an input L/Pd ratio of << 1 with no impact on reaction kinetics.

  DOI：

  10.1021/acs.joc.8b02214
• 作为产物：
  描述：

  2-溴-1,3-二苯基丙烷-1,3-二酮 在 正丁基锂 、 溶剂黄146 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 正己烷 为溶剂， 反应 3.5h， 生成 5-二叔丁基膦-1′,3′,5′-三苯基-1′H-[1,4′]二吡唑
  参考文献：
  名称：

  Bippyphos配体家族的简化合成和交叉偶联应用

  摘要：

  我们描述了Bippyphos，1的有效制备方法。Bippyphos的关键前体5是通过二锅2的一锅溴化反应，然后用吡唑烷基化并与苯肼缩合制备的。5的锂化并用二叔丁基氯膦捕获，得到Bippyphos，1。使用这种方法，我们已经制备了Bippyphos的几种衍生物，以探测该膦配体家族的结构和活性之间的关系。我们还证明了这些配体在钯催化的胺化反应和其他交叉偶联反应中的效用。

  DOI：

  10.1021/op7002858
• 作为试剂：
  描述：

  tert-butyl 9,11-dioxo-8-(2,4,6-trimethoxybenzyl)-2,8-diazaspiro[5.5]undecane-2-carboxylate 在 5-二叔丁基膦-1′,3′,5′-三苯基-1′H-[1,4′]二吡唑 、 4-二甲氨基吡啶 、 tris-(dibenzylideneacetone)dipalladium(0) 、 ammonium acetate 、 碳酸氢钠 、 三乙胺 、 三氟乙酸 、 potassium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  PIPERINDIN-ONES DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF

  摘要：

  Piperidin-ones compound of formula (I), the preparation method thereof, pharmaceutcal compositions comprising the compounds, and the pharmaceutical uses for the treatment of disorders are disclosed.

  公开号：

  WO2024125451A1

文献信息

• 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES
  申请人：Bhattacharya Samit K.

  公开号：US20110230461A1

  公开（公告）日：2011-09-22

  The present invention provides a compound of Formula (I) or a pharmaceutically salt thereof wherein R 1 , R 2 , Ra, L, Z, Z 1 and Z 2 are as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.

  本发明提供了一种式（I）的化合物或其药用盐，其中R1、R2、Ra、L、Z、Z1和Z2如本文所定义，其作为胃泌素拮抗剂或逆向激动剂；以及其药物组合物；以及通过胃泌素受体拮抗作用治疗疾病、紊乱或病况的方法。
• Aryl Ether-Base Kinase Inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20130237555A1

  公开（公告）日：2013-09-12

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

  本公开涉及一般可抑制AAK1（适配器相关激酶1）的化合物，包括这些化合物的组合物，以及抑制AAK1的方法。
• TRPV1 Antagonists
  申请人：AbbVie Inc.

  公开号：US20130158067A1

  公开（公告）日：2013-06-20

  Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X 1 , L, R x , R y , R z , A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  披露于此的是公式（I）的化合物： 或其药用可接受的盐，其中X 1 ，L，R x ，R y ，R z ，A，m，n，p，q，s，以及位置a和b如说明书所述定义。还披露了包含此类化合物的组合物以及使用此类化合物和组合物治疗状况和失调的方法。
• Pd₂dba₃/Bippyphos: A Robust Catalyst System for the Hydroxylation of Aryl Halides with Broad Substrate Scope
  作者：Christopher B. Lavery、Nicolas L. Rotta-Loria、Robert McDonald、Mark Stradiotto

  DOI：10.1002/adsc.201300088

  日期：2013.3.25

  4′]bipyrazole (Bippyphos) is shown to be a robust and efficient catalyst system for the hydroxylation of structurally diverse (hetero)aryl halides under mild conditions and with broad substrate scope. Included in this reactivity survey is the successful synthesis of substituted benzofurans and related heteroatomic derivatives, which are formed via the hydroxylation of 2‐haloalkynylarenes. Notably, a significant

  三（二亚苄基丙酮）（0）（钯的混合物2 DBA 3）和5-（二-叔-butylphosphino）-1'，3'，5'-三苯基-1' ħ - [1,4'] bipyrazole （Bippyphos）被证明是在温和的条件下和广泛的底物范围内用于结构多样的（杂）芳基卤化物羟基化的强大而有效的催化剂体系。反应性调查中包括成功合成的取代苯并呋喃和相关杂原子衍生物，它们是通过2-卤代炔烃的羟基化 值得注意的是，本文报道的大量反应是在室温下进行的，并且我们已经证明，可以在空气中使用未纯化的溶剂在台式机上进行反应，而与在惰性气氛条件下进行的相关转化相比，反应活性的损失可忽略不计。我们还在本文中报道了第一个晶体学表征的（Bippyphos）Pd（II）配合物，该配合物证实了该合成有用的配体以类似于Buchwald的联芳基膦配体类别的方式采用双齿结合基序的能力。
• [EN] NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES AZOTÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：BLACK DIAMOND THERAPEUTICS INC

  公开号：WO2021127397A1

  公开（公告）日：2021-06-24

  The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.

  本公开涉及式(I)的化合物，以及其药学上可接受的盐和立体异构体。本公开还涉及制备这些化合物的方法，包含这些化合物的组合物，以及将这些化合物用作受体酪氨酸激酶的抑制剂的方法，特别是ErbB受体的致癌突变体，例如在癌症治疗中的应用。